Comment on West et al. "Identifying and quantifying exposures involving counterfeit opioid analgesic products".

Clin Toxicol (Phila)

Department of Addiction Psychiatry, Ministry of Health and Welfare Department of Counseling, Clinical and Industrial/Organizational Psychology, Taoyuan Psychiatric Center, Ming Chuan University, Taoyuan City, Taiwan.

Published: January 2025

Download full-text PDF

Source
http://dx.doi.org/10.1080/15563650.2024.2421862DOI Listing

Publication Analysis

Top Keywords

comment west
4
west et al
4
et al "identifying
4
"identifying quantifying
4
quantifying exposures
4
exposures involving
4
involving counterfeit
4
counterfeit opioid
4
opioid analgesic
4
analgesic products"
4

Similar Publications

Current status of drug therapy for chronic hepatitis B.

World J Gastroenterol

January 2025

Division of Liver Surgery, Department of General Surgery and Laboratory of Liver Surgery, and State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.

In this editorial, we comment on the article by Meng . Chronic hepatitis B (CHB) is a significant global health problem, particularly in developing countries. Hepatitis B virus (HBV) infection is one of the most important risk factors for cirrhosis and hepatocellular carcinoma.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!